glp 1 agonists in development GLP-1 Receptor and Research to Treat Overeating and Substance Use Disorders Market Overview: GLP-1 Agonists and
Description
GLP-1 drugs have become a game-changer in treating obesity and type 2 diabetes, forecast to reach a $100 billion market value by 2030
Read or listen now!
Why Microdosing
Key Mechanisms of Action : GLP-1 Receptor Agonism (Activation): Similar to current weight-loss drugs, it mimics the GLP-1 hormone to increase satiety (feeling full) and reduce appetite
Partly through these actions, GLP-1 receptor agonism was shown to reduce cardiovascular disease (CVD) in people with T2D with previous CVD or at high-risk thereof
GIP Receptor Antagonism (Blocking): Unlike many dual-agonists that activate GIP, MariTide blocks it
